Miniscule non-invasive glucose monitoring SoC from Movano completes tests and heads for wearable prototype system studies
Painless, needle-free, non-invasive continuous glucose monitoring has become the target of many a biotech firm and healthtech startup over recent years; however, only a few seem to make the same sort of progress as Movano. The company behind the Movano Ring, which can measure various biomarkers to offer data in regard to the wearer’s health (temperature, blood oxygen, etc.), has offered an update about its work in the realm of pain-free, non-invasive blood sugar monitoring. The firm has been testing its custom SoC and has now validated its functionality, with the next step being clinical studies as part of a prototype wearable.
Movano has managed to shrink four integrated circuits (ICs) to form a single “multi-chip architecture” sensor. So as the company claims, the SoC then has “the power of 4 chips in 1” while coming in at a handily minute size of 4 mm x 6.7 mm, which is much smaller than something like the A15 Bionic SoC that comes in the iPhone 13 Pro (8.58 mm x 12.55 mm). This little Movano SoC utilizes mmWave radio frequencies to measure the relevant biomarkers, which could be either for non-invasive glucose measurements or for cuffless blood pressure monitoring. Reportedly, four years of development and investment have been required to create this new technology.
Movano describes the chip as “the smallest ever radio frequency (RF)-enabled integrated circuit (IC) designed specifically for blood pressure or glucose monitoring systems” and assures that the SoC is precise. This will be further tested in the next stage of R&D that will involve implementing the sensor into a “prototype system”, which could be a wearable in the form of a smartwatch, or perhaps the firm might even plan to integrate its non-invasive glucose monitoring system into a newer version of the aforementioned Movano Ring.
What will matter most to many people with type 1 or type 2 diabetes will be the “triple-A” factor: Availability, Affordability, Accuracy. When will the device be available, will it be affordable to the majority of diabetics, and will such a novel non-invasive CGM be able to offer the same sort of vital accuracy as finger prick blood tests? As is typical with many of these devices, there is currently no price estimate or predicted release date from Movano yet. Competition in this particular arena is quite fierce, with some companies already either claiming to have a non-invasive continuous glucose monitor ready for market or targeting the next year or two for release.
PLEASANTON, Calif., May 12, 2022 /PRNewswire/ -- Movano Inc. (Nasdaq: MOVE), a purpose-driven healthcare solutions company at the intersection of medtech and consumer devices, announces it has successfully validated the functionality of its proprietary and patented system-on-a-chip (SoC). At 4 mm x 6.7 mm, the SoC combines multiple antennas and a variety of frequencies in the smallest ever radio frequency (RF)-enabled integrated circuit (IC) designed specifically for blood pressure or glucose monitoring systems. Movano built the integrated sensor from the ground up in an effort to achieve an unprecedented level of precision in health monitoring, and has invested four years into this novel non-invasive sensor technology.
Movano's proprietary and patented System-on-a-Chip, the smallest ever custom RF-enabled IC designed for blood pressure and glucose monitoring.
"The majority of current wearables on the market use off-the-shelf optical sensors, whereas Movano has made a significant investment into creating its own fully integrated mmWave sensor simply because the standard approach cannot deliver the level of accuracy, flexibility of form factor or cost we are aiming to achieve," said Dr. John Mastrototaro, CEO of Movano. "RF offers the opportunity for increased accuracy in health monitoring across a broader population because it is not affected by different skin pigmentation, as can be the case with optical sensors. In addition, our solution is fabricated using the latest processes in semiconductor technology, meaning the size can be smaller and the materials more cost-effective – giving us greater flexibility in the design of future medical devices and in our ability to offer a solution that's affordable, so we can reach a larger, more diverse segment of people. In preparation for additional clinical studies, we're integrating the SoC into a new, smaller prototype system to make further advancements on our quest to accurately measure blood pressure and glucose."
This key milestone highlights Movano's unique investment in R&D, and represents the culmination of a massive undertaking, led by engineers with decades of experience in RF, to shrink its multi-chip architecture from four ICs into a single integrated sensor. Alongside this milestone, the Company was granted a new patent, marking a total of seven U.S. patents currently issued to Movano. The new patent protects innovations around Movano's multi-band chip design, which uses signal diversity and advanced signal processing capabilities, and will be integrated into various devices in the future.
For more information on Movano, visit www.movano.com.
About Movano Inc.
Founded in 2018, Movano Inc. (NASDAQ:MOVE) is developing a platform to deliver purpose-driven healthcare solutions at the intersection of medtech and consumer devices. We are on a mission to empower and inspire you to live a healthier, happier life by combining vital health data with personalized intelligent feedback in stylish form factors. Movano plans to add medically validated data to its platform that caretakers and healthcare professionals can use to help you identify, treat or better manage the symptoms of chronic conditions.
Forward Looking Statements
This press release contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results; product development and features, product releases, clinical trial and regulatory initiatives; our strategies, positioning and expectations for future events or performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption "Risk Factors." Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.